SG-1827

Phase Ia study objectives: Primary objectives: 1) Safety and tolerability; 2) Explore MTD or MAD. Secondary objectives: 1) Evaluate the PK and PD characteristics of SG1827 in subjects with advanced malignant solid tumors; 2) Evaluate the immunogenicity of SG1827; 3) Evaluate the preliminary anti-tumor efficacy of SG1827 monotherapy. Phase Ib study objectives: Primary objectives: 1) Safety and tolerability; 2) Determine the RP2D of SG1827 in subjects with advanced malignant solid tumors; 3) Evaluate the anti-tumor activity of SG1827 in subjects with advanced malignant solid tumors. Secondary objectives: 1) Evaluate other efficacy of SG1827 in subjects with advanced malignant solid tumors; 2) Evaluate PK and PD characteristics; 3) Evaluate the immunogenicity of SG1827. Exploratory objectives: Explore biomarkers in tumor tissue/blood that potentially predict the efficacy of SG1827.